Cencora Agrees to Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Spanning 21 States

Cencora To Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Across 21 States

Drug distributor Cencora has signed a definitive agreement to acquire American Oncology Network (AON), a physician‑led network of more than 350 cancer care providers in 21 states, in a deal that values AON at $2.4 billion, the companies announced on Oct. 21.

For patients receiving chemotherapy, infusions, or other treatment at an AON‑affiliated practice, nothing changes at this time. The transaction awaits AON stockholder approval and regulatory clearance, and Cencora assures that clinical decisions will remain with AON’s physicians.

The agreement follows a broader trend. Drug wholesalers are purchasing management companies behind independent cancer practices, a shift that may reshape how community clinics procure drugs, leverage data, and engage with insurers.

Inside the $2.4 Billion Agreement

Cencora, formerly AmerisourceBergen, already holds roughly 4 % of AON and agreed to acquire the equity it did not own. The enterprise value comprises $2.3 billion at closing plus contingent value rights worth up to $100 million, per terms reported by MarketScreener.

Certain AON stockholders may roll over up to 25 % of their equity. If they do, Cencora expects to pay approximately $1.7 billion to raise its ownership to 75 %. AON’s board approved the deal on the unanimous recommendation of a special committee of independent and disinterested directors.

AON, headquartered in Fort Myers, Florida, launched in 2018 as a management services organization, or MSO. It delivers business and clinical support for community oncology practices, including specialty pharmacy, pathology and lab services, and care coordination. The transaction would expand Cencora’s oncology MSO into 12 additional states.

“With the addition of AON to our leading MSO network, we will enhance our capabilities for independent practices, strengthening patient access to high‑quality, cost‑effective care, while fortifying our growth platform to drive long‑term value for our stakeholders,” Cencora President and CEO Robert P. Mauch stated in the company’s regulatory filing. Those statements reflect the company’s perspective, and no independent data yet exist on patient outcomes under the new ownership.

A Second Cancer Network After OneOncology

This is Cencora’s second major oncology network acquisition in under a year. In December 2025, the company agreed to purchase a majority stake in OneOncology for roughly $5 billion in cash, as reported by Fierce Healthcare. OneOncology serves approximately 1,750 providers across more than 565 care locations, according to Becker’s ASC Review.

Analysts at Evercore indicated that the two networks target different market segments, with AON focused on smaller practices and OneOncology on larger ones, although they overlap in many areas. Given Cencora’s prior investment in AON since 2020 and its role as the network’s drug distributor, integration risk was deemed limited. Analysts project a closing in late March 2027.

Cancer Patients Who May Notice Changes

Most patients will likely experience no immediate impact. Over time, changes could arise in billing systems, patient portals, pharmacy services, care‑navigation tools, or the insurers with which practices contract.

Those most likely to feel the effects include individuals in active treatment, older adults on Medicare, patients incurring high out‑of‑pocket costs for infused medications, and rural residents who rely on community clinics rather than distant academic centers.

Patients can take proactive steps now. Confirm that their oncologist’s practice remains in network with their insurance plan, especially during this fall’s open enrollment. Ask the practice’s financial counselor about copay assistance, manufacturer discount programs, and charity care options. Maintain records of treatment plans and recent bills, and report any unexpected billing changes promptly.

Medicare patients face additional considerations. Many community oncology practices provide infused drugs covered under Medicare Part B, and those without supplemental coverage typically owe 20 % coinsurance after the deductible. Uncertain about coverage? Contact the State Health Insurance Assistance Program for free guidance before Medicare open enrollment concludes on Dec. 7.

Patients should not alter or postpone cancer treatment based on business news. For care questions, they should consult their oncology team. Fierce Healthcare notes that Cencora will address the deal during its Nov. 4 earnings call.

Key Questions Answered

What Cencora announced? Cencora signed a definitive agreement to acquire American Oncology Network (AON), a physician‑led network of over 350 cancer care providers across 21 states, valued at $2.4 billion.

How large is American Oncology Network? AON supports more than 350 cancer care providers across 21 states and is based in Fort Myers, Florida.

Will patients’ doctors change? Cencora assures that clinical decisions will remain with AON’s physicians, and the transaction has not yet closed.

When will the deal close? It requires AON stockholder approval and regulatory clearance. Analysts at Evercore projected a closing in late March 2027.

Could the deal affect cancer care costs? The long‑term impact is uncertain. Patients should monitor potential shifts in billing, insurance networks, and pharmacy services and seek clarification early.

What should current patients do now? Confirm in‑network status during open enrollment, inquire about financial assistance, keep billing records, and continue treatment as planned with the oncology team.

Source link